A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors

Assay and Drug Development Technologies

Volumn 11, Issue 6, 2013, Pages 367-381

  Du, Yuhong ^a,b   Fu, Robert W ^a   Lou, Bin ^a   Zhao, Jing ^a   Qui, Min ^a,b   Khuri, Fadlo R ^a   Fu, Haian ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DY 647; EUROPIUM; FOBISIN 101; ISOTOPE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN INHIBITOR; R 18; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; ISOTOPE LABELING; MOLECULAR ELECTRONICS; MOLECULE; NONHUMAN; PEPTIDE LIBRARY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL NOISE RATIO; TIME RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER; TITRIMETRY;

14-3-3 PROTEINS; BCL-ASSOCIATED DEATH PROTEIN; DIMETHYL SULFOXIDE; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS;

EID: 84882985255     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.507     Document Type: Article

References (40)

1. Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000;40:617-647. (Pubitemid 30340695)
2. Tinti M, Johnson C, Toth R, Ferrier DE, Mackintosh C: Evolution of signal multiplexing by 14-3-3-binding 2R-ohnologue protein families in the vertebrates. Open Biol 2012;2:120103.
3. Pozdeyev N, Taylor C, Haque R, et al.: Photic regulation of arylalkylamine Nacetyltransferase binding to 14-3-3 proteins in retinal photoreceptor cells. J Neurosci 2006;26:9153-9161. (Pubitemid 44359842)
4. Jin J, Smith FD, Stark C, et al.: Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 2004;14:1436-1450. (Pubitemid 39123741)
5. Meek SE, Lane WS, Piwnica-Worms H: Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins. J Biol Chem 2004;279:32046- 32054. (Pubitemid 39014649)
6. Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H: 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol 2011;22:705-712.
7. Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol 2006;16:162-172. (Pubitemid 43796128)
8. Dougherty MK, Morrison DK: Unlocking the code of 14-3-3. J Cell Sci 2004;117(Pt 10):1875-1884. (Pubitemid 38745122)
9. Wilker E, Yaffe MB: 14-3-3 proteins - a focus on cancer and human disease. J Mol Cell Cardiol 2004;37:633-642. (Pubitemid 39194555)
10. Qi W, Martinez JD: Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 2003;160:217-223. (Pubitemid 36897502)
11. Li Z, Zhao J, Du Y, et al.: Down-regulation of 14-3-3zeta suppresses anchorageindependent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 2008;105:162-167.
12. Fan T, Li R, Todd NW, et al.: Up-regulation of 14-3-3{zeta} in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007;67:7901- 7906. (Pubitemid 47281386)
13. Neal CL, Yao J, Yang W, et al.: 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69:3425-3432.
14. Lin M, Morrison CD, Jones S, Mohamed N, Bacher J, Plass C: Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer 2009;125:603-611.
15. Inglese J, Johnson RL, Simeonov A, et al.: High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 2007;3:466-479. (Pubitemid 47080373)
16. Du Y, Masters SC, Khuri FR, Fu H: Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay. J Biomol Screen 2006;11: 269-276.
17. Wu M, Coblitz B, Shikano S, et al.: SWTY - a general peptide probe for homogeneous solution binding assay of 14-3-3 proteins. Anal Biochem 2006; 349:186-196. (Pubitemid 43186018)
18. Du Y, Khuri FR, Fu H: A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides. Curr Chem Genomics 2008;2:40-47.
19. Wu M, Coblitz B, Shikano S, et al.: Phospho-specific recognition by 14-3-3 proteins and antibodies monitored by a high throughput label-free optical biosensor. FEBS Lett 2006;580:5681-5689. (Pubitemid 44515089)
20. Zhao J, Du Y, Horton JR, et al.: Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci USA 2011;108:16212-16216.
21. Corradi V, Mancini M, Manetti F, Petta S, Santucci MA, Botta M: Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 proteinprotein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg Med Chem Lett 2010;20:6133-6137.
22. Wu H, Ge J, Yao SQ: Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. Angew Chem Int Ed Engl 2010;49:6528-6532.
23. Ottmann C: Small-molecule modulators of 14-3-3 protein-protein interactions. Bioorg Med Chem 2012; pii: S0968-0896(12)00921-2.
24. Sills MA, Weiss D, Pham Q, Schweitzer R, Wu X, Wu JJ: Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-214. (Pubitemid 34734329)
25. Glickman JF, Wu X, Mercuri R, et al.: A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen 2002; 7:3-10. (Pubitemid 34208857)
26. Wu X, Glickman JF, Bowen BR, Sills MA: Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen 2003;8:381-392.
27. Du Y, Nikolovska-Coleska Z, Qui M, et al.: A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions. Assay Drug Dev Technol 2011;9:382-393.
28. Thorne N, Auld DS, Inglese J: Apparent activity in high-throughput screening: Origins of compound-dependent assay interference. Curr Opin Chem Biol 2010;14:315-324.
29. Masters SC, Yang H, Datta SR, Greenberg ME, Fu H: 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol 2001;60:1325-1331. (Pubitemid 33144903)
30. Masters SC, Fu H: 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 2001;276:45193-45200.
31. Zhang L, Chen J, Fu H: Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc Natl Acad Sci USA 1999;96:8511-8515. (Pubitemid 29354822)
32. Wang B, Yang H, Liu YC, et al.: Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999;38:12499-12504.
33. Fu H, Coburn J, Collier RJ: The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc Natl Acad Sci USA 1993;90:2320-2324. (Pubitemid 23078618)
34. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
35. Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B: HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr Chem Genomics 2009;3:22-32.
36. Subramanian RR, Masters SC, Zhang H, Fu H: Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp Cell Res 2001;271: 142-151. (Pubitemid 33071001)
37. Hekman M, Albert S, Galmiche A, et al.: Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding. J Biol Chem 2006;281:17321-17336.
38. Petosa C, Masters SC, Bankston LA, et al.: 14-3-3zeta binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J Biol Chem 1998;273:16305-16310. (Pubitemid 28311408)
39. Soares KM, Blackmon N, Shun TY, et al.: Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol 2010;8:152-174.
40. Zhang L, Wang H, Liu D, Liddington R, Fu H: Raf-1 kinase and exoenzyme S interact with 14-3-3zeta through a common site involving lysine 49. J Biol Chem 1997;272:13717-13724. (Pubitemid 27224807)